4
Registered trials
0
Recruiting
4
Unique sponsors
4
Unique IMPs
4
Commercial trials
Drug classes (ATC)
—
ATC code not specified
3
B
Haematology (ATC B)
1
C
Cardiology (ATC C)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
3 substances
Supportive / diluent
1 substance
Phase I (Other):
4
Phase I (Other)
4 trials-
EndedAmylyx Pharmaceuticals EMEA B.V. CommercialIMP not specified
-
EndedAstraZeneca AB CommercialAZD3427; DOPAMINE HYDROCHLORIDE; O15-WATER; SODIUM CHLORIDE
-
EndedBoehringer Ingelheim International GmbH CommercialIMP not specified
-
EndedJanssen - Cilag International CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Amylyx Pharmaceuticals EMEA B.V. | Commercial | 1 | Phase I (Other) | 0 |
| AstraZeneca AB | Commercial | 1 | Phase I (Other) | 0 |
| Boehringer Ingelheim International GmbH | Commercial | 1 | Phase I (Other) | 0 |
| Janssen - Cilag International | Commercial | 1 | Phase I (Other) | 0 |
New trials by year
2023
1
2024
3